Losartan Potassium (DuP 753) - 10mM in DMSO, high purity , CAS No.124750-99-8(DMSO), Type-1 angiotensin II receptor antagonist

Item Number

L408919

• Synonyms: MK 954 | 2-​butyl-​4-​chloro-​1-​[[2'-​(2H-​tetrazol-​5-​yl)​[1,​1'-​biphenyl]​-​4-​yl]​methyl]​-1H-​imidazole-​5-​methanol, potassium salt (1:1)
• Specifications & Purity: 10mM in DMSO
• Biochemical and Physiological Mechanisms: Losartan Potassium (DuP 753, MK 954) is an angiotensin II receptor antagonist, competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.
• Storage Temp: Store at -80°C
• Shipped In: Ice chest + Ice pads
• Action Type: ANTAGONIST
• Mechanism of action: Type-1 angiotensin II receptor antagonist

Product Description

Information

Losartan Potassium (DuP 753) Losartan Potassium (DuP 753, MK 954) is an angiotensin II receptor antagonist, competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.
In vitro

In vivo

Losartan (180 mg/d) causes significant increases in plasma angiotensin II and angiotensin-(1-7) in monkeys with diet-induced hypercholesterolemia. Losartan (180 mg/d) reduces the extent of fatty streak in the aorta, the coronary arteries, and the carotid arteries by approximately 50% in monkeys with diet-induced hypercholesterolemia. Losartan reduces the susceptibility of LDL to in vitro oxidation, serum levels of monocyte chemoattractant protein-1, and circulating monocyte CD11b expression in monkeys with diet-induced hypercholesterolemia. Losartan (0.6 g/L in their drinking water) prevents elastic fiber fragmentation and blunted TGF-β signaling in the aortic media in pregnant Fbn1^C1039G/+ mice, as evidenced by reduced nuclear accumulation of pSmad2. Losartan (0.6 g/L in their drinking water) shows a reduction in distal airspace caliber in pregnant Fbn1^C1039G/+ mice. Losartan (0.6 g/L in their drinking water) improves disease manifestations in the lungs, an event that cannot plausibly relate to improved hemodynamics in pregnant Fbn1^C1039G/+ mice. Losartan (5 mg/kg/d) leads to a significant decrease in the development of atherosclerotic lesions in the apo E deficient mice. Losartan (5 mg/kg/d) significantly reduces the susceptibility of the mice LDL to lipid oxidation following its incubation with CuSO4 in the apo E deficient mice. Losartan (10 mg/kg) administration increases blood angiotensin levels four fold to six fold, blood BK levels are unchanged in male Sprague Dawley rats. Losartan (10 mg/kg) increases plasma renin levels 100-fold, plasma angiotensinogen levels decreases to 24% of control and plasma aldosterone levels are unchanged in male Sprague Dawley rats.
Cell Data

cell lines：RAW 267.4 macrophages

Concentrations：

Incubation Time：

Powder Purity:≥99%